Trial Profile
Phase 1 Study to Evaluate the Safety, Feasibility and Immunologic Correlatives of Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 19 Oct 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Kaposi's sarcoma; Skin cancer
- Focus Adverse reactions
- 02 Aug 2021 Status changed from active, no longer recruiting to completed.
- 17 Feb 2021 Planned End Date changed from 1 Jun 2022 to 30 Jun 2021.
- 17 Feb 2021 Planned primary completion date changed from 1 Apr 2021 to 30 Jun 2021.